CD19 + CD22 CAR-T

CD19 + CD22 CAR-T refers to a chimeric antigen receptor T cell therapy in which human T lymphocytes are genetically engineered to express receptors targeting both CD19 and CD22 antigens. These antigens are transmembrane phosphoglycoproteins commonly expressed on B-lineage cells and are frequently overexpressed in malignant B-cell disorders such as acute lymphoblastic leukemia (ALL). By targeting both CD19 and CD22 simultaneously—either through cotransduction with separate CARs or via a single bicistronic or tandem CAR construct—this therapy aims to reduce the risk of antigen-negative relapse that can occur with single-antigen targeted therapies. The mechanism of action involves the redirected cytotoxic activity of modified T cells against malignant B cells expressing either or both target antigens, leading to immunostimulation and tumor cell lysis. This approach is under clinical investigation primarily for relapsed/refractory B-cell acute lymphoblastic leukemia[2][3][4][5][8].

Other names

anti-cd19/cd22 car t cellsautologous anti-cd19/cd22 car-t cellstan-car t cellsdual-targeting cd19/cd22 car-t